@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAl2Zb7xbOZa14hawvlmL9ZzsnNRmvWFJx9MKbs7Yn5ZU> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAl2Zb7xbOZa14hawvlmL9ZzsnNRmvWFJx9MKbs7Yn5ZU#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix entrez: <http://www.ncbi.nlm.nih.gov/gene/> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix rgd: <http://rgd.mcw.edu/rgdweb/report/gene/main.html?id=> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 geneProductOf: entrez:24179 ;
    a Protein: .
  sub:_2 geneProductOf: rgd:620795 ;
    a Protein: .
  sub:_3 occursIn: species:10116 ;
    rdf:object sub:_2 ;
    rdf:predicate belv:increases ;
    rdf:subject sub:_1 ;
    a rdf:Statement .
  sub:assertion rdfs:label "p(EGID:24179) -> p(RGD:Src)" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_5 ;
    pav:version "1.4" .
  sub:_4 prov:value "When VSMCs were pre-treated with geldanamycin, a Src inhibitor, and then stimulated with Angiotensin II, geldanamycin completely blocked the Angiotensin II dependent phosphorylation of p130Cas.The cells were next pre-treated with PP1, a specific Src family kinase inhibitor, and then stimulated with Angiotensin II, the tyrosine phosphorylation of p130Cas was completely eliminated, indicating that an active Src family kinase is critical for Angiotensin II mediated p130Cas tyrosine phosphorylation." ;
    prov:wasQuotedFrom pubmed:9648724 .
  sub:_5 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:9648724 ;
    prov:wasDerivedFrom beldoc: , sub:_4 .
}
sub:pubinfo {
   this: dcterms:created "2014-07-03T14:31:00.047+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}